Teva Pharmaceutical Industries has raised its fiscal year 2026 sales guidance while maintaining its adjusted earnings per share (EPS) outlook, driven by robust performance in its innovative drug portfolio. The New York-listed pharmaceutical giant reported second-quarter adjusted earnings of $0.02 per share, missing the consensus estimate of $0.25, but delivered sales of $4.142 billion, beating the Wall Street consensus of $4.047 billion. This top-line strength was primarily fueled by a 43% year-over-year local currency growth in key innovative brands Austedo, Ajovy, and Uzedy, which collectively generated over $1 billion in revenues during the quarter.

The divergence between revenue strength and earnings miss highlights ongoing margin pressures, particularly within the generics segment. While sales decreased 1% overall (3% in local currency), the decline was attributed to lower revenues from generic products, specifically lenalidomide capsules in the U.S. Conversely, the biosimilars portfolio performed strongly and is on track to deliver $800 million in revenues by 2027. Management indicated that the company remains on track to meet its 2027 financial growth targets, expecting continued margin expansion driven by its innovative portfolio despite challenges in the generics sector.

Guidance Revisions

Teva maintained its FY26 adjusted EPS guidance at $1.91-$2.11, which includes $0.66 per share of Emalex expenses. However, the company marginally raised its FY26 sales guidance from $16.40 billion-$16.80 billion to $16.50 billion-$16.85 billion, surpassing the analyst consensus of $16.618 billion. Additionally, Teva raised its FY26 revenue outlook for its key innovative brands to approximately $3.7 billion, reflecting around 17% year-over-year growth at the midpoint.

NYSE Listing Transition

In a significant corporate development, Teva announced the replacement of its American Depositary Share (ADS) program with the direct listing of its ordinary shares on the New York Stock Exchange (NYSE). ADSs will be exchanged on a one-for-one basis for ordinary shares, which commence trading on the NYSE on Monday, Sept. 14. The transition aims to broaden Teva’s shareholder base, support its potential inclusion in leading indices, and optimize cost-of-capital. Following the earnings report, Teva shares were up 9.25% at $34.60.

What the Numbers Show

The most critical analytical takeaway is the accelerating shift in Teva’s revenue mix toward higher-margin innovative therapies. While the generics segment continues to face headwinds from competition and specific product declines like lenalidomide, the innovative brands Austedo, Ajovy, and Uzedy are growing at a rapid pace (43% YoY). This suggests that Teva’s strategic pivot away from reliance on low-margin generics is yielding tangible results. The maintenance of EPS guidance despite the Q2 miss indicates that management expects these innovative brand gains to offset generic weaknesses in the latter half of the year, supported by a robust pipeline including potential launches of olanzapine and ecopipam.

Teva Pharmaceutical Industries and Samsung Bioepis have entered a license and commercialization agreement for OPUVIZ, an aflibercept biosimilar referencing Eylea, in Canada. The partnership aims to bring the biosimilar to the Canadian market, leveraging the strengths of both companies.

Under the agreement, Samsung Bioepis is responsible for the registration and manufacture of the products. Teva Canada, a subsidiary of Teva Pharmaceutical Industries, will oversee commercialization activities. This division of responsibilities aligns with each company's expertise.

OPUVIZ is a biosimilar referencing Eylea, a treatment for various retinal diseases. The agreement marks a significant step in expanding access to biosimilar treatments in Canada.

Key Responsibilities

The collaboration highlights the growing importance of biosimilars in the pharmaceutical market. Both companies are expected to leverage their capabilities to ensure a successful launch.